ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
05. Oktober 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
26. April 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...